
Britain has become the first country to approve an antiviral COVID-19 treatment that can be taken as a pill at home.
The UK national medicines regulator, the MHRA, announced on Nov. 4 that the antiviral Lagevrio (molnupiravir) had been authorised to treat mild to moderate COVID-19—in those with other risk factors, such as obesity, diabetes, or those over 60 years old.
“Today is a historic day for our country, as the UK is now the first country in the world to approve an antiviral that can be taken at home for COVID-19,” said UK health secretary Sajid Javid in a statement.
“We are working at pace across the government and with the NHS to set out plans to deploy molnupiravir to patients through a national study as soon as possible."
“This antiviral will be an excellent addition to our armoury against COVID-19.”
The drug, from Ridgeback Biotherapeutics and Merck Sharp & Dohme (MSD), works by interfering with the virus’s replication.
It prevents the virus from multiplying, keeping levels low in the body and therefore reducing the severity of the disease.